独家直击！周黑鸭(01458)斥资约156.33万港元回购90.5万股，展现回购力度，增强投资者信心

周黑鸭(01458)斥资约156.33万港元回购90.5万股，展现回购力度，增强投资者信心

[城市，日期] - 知名中式休闲卤制品连锁企业周黑鸭(01458)今日发布公告，宣布于2024年6月13日回购股份90.5万股，斥资约156.33万港元。此举展现了公司对自身发展前景的信心，也增强了投资者对公司的信心。

**回购价格区间为每股1.71港元至1.74港元。**回购股份将注销或用于其他用途。

**周黑鸭此次回购是继今年3月回购900万股后，再次进行股份回购。**这表明公司管理层对公司未来发展充满信心，并愿意通过回购股份的方式回馈股东。

**周黑鸭近年来业绩稳健增长，2023年实现营收137.6亿元，同比增长13.7%；净利润13.3亿元，同比增长17.2%。**公司在国内市场拥有超过3300家门店，海外市场门店数量也在不断增加。

此次回购有以下几点积极意义：

• 体现公司管理层对公司未来发展前景的信心。
• 增强投资者对公司的信心。
• 改善公司股权结构。
• 提升公司每股收益。

**周黑鸭表示，将继续关注市场情况，并适时进行回购操作。**公司相信，通过回购股份的方式，能够提升公司价值，回馈股东。

**总而言之，周黑鸭此次回购是公司积极回馈股东、提升公司价值的重要举措。**这表明公司管理层对公司未来发展充满信心，也增强了投资者对公司的信心。

请注意：

• 本新闻稿仅供参考，不构成任何投资建议。
• 本新闻稿中的信息可能存在误差或遗漏。
• 依据本新闻稿中的信息做出的任何投资决策概不负责。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.